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Phagocytosis of dying cells constitutes an important mechanism of antigen capture for the
cross-priming of CD8+ T cells. This process has been shown to be critical for achieving
tumor and viral immunity. While most studies have focused on the mechanisms inherent
in the dendritic cell that account for exogenous antigen accessing MHC I, several recent
reports have highlighted the important contribution made by the antigen donor cell. Specif-
ically, the cell stress and cell death pathways that precede antigen transfer are now known
to impact cross-presentation and cross-priming. Herein, we review the current literature
regarding a role for macroautophagy within the antigen donor cell. Further examination of
this point of immune regulation is warranted and may contribute to a better understanding
of how to optimize immunotherapy for treatment of cancer and chronic infectious disease.
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INTRODUCTION
Signiﬁcant evidence for an indirect pathway for the loading of
MHC class I molecules has emerged over the last 35 years (Bevan,
1976; Rock et al., 1990). The most compelling data comes from
in vivo experiments in mouse models demonstrating that viral,
tumor, and histocompatibility antigens can be transferred from
MHC-mismatched donor cells to host bone marrow derived con-
ventional dendritic cells (cDCs), and elicit antigen-speciﬁc CTL
responses that are restricted to self MHC molecules (Falo et al.,
1995; Reis e Sousa and Germain, 1995; Sigal et al., 1999; Mell-
man and Steinman, 2001; Boon et al., 2006; Petersen et al., 2010).
Bevan (1976) originally coined this phenomenon“cross-priming,”
as antigen is “crossing the MHC barrier” that had initially been
invoked in the generation of MHC class I peptide epitopes. As it is
now understood that the activation of naïve T cells is a property
restricted to cDCs, these in vivo observations offered a solution to
the question of how CD8+ T cells are activated for the targeting of
cells which express antigen that is not directly expressed by cDCs.
Examples of such antigen include tumor-restricted proteins and
viruses which do not infect professional antigen presenting cells
(APCs; e.g., human papillomavirus; Fausch et al., 2003). While
these observations indicate that the immune system possesses
a natural mechanism by which exogenous antigens may access
MHC I molecules of APCs, there remains much to be discovered
regarding the mechanisms of antigen transfer.
Our in vitro studies and the in vivo workof others demonstrated
that immature cDCs are capable of capturing antigen derived from
internalized dying cells and cross-presenting donor antigen on
MHC I molecules for engagement of CD8+ T cells (Albert et al.,
1998, 2001; Kurts et al., 2010; Pang and Neefjes, 2010; Flinsenberg
et al., 2011). cDC trafﬁcking of tissue-restricted antigen derived
from internalized dying cells has been demonstrated for models of
gut-, skin-, and pancreas-restricted protein antigen (Huang et al.,
2000; Belz et al., 2002; Scheinecker et al., 2002; Turley et al., 2003).
In the latter model system, the use of transgenic mice expressing
inhibitors of apoptosis in beta cells and the in vivo injection of
biochemical modulators of death pathways have conﬁrmed the
critical role for cell death in both antigen transfer and T cell acti-
vation (Hugues et al., 2002; Turley et al., 2003; Giodini and Albert,
2010; Locher et al., 2010; Flinsenberg et al., 2011).
Over the last decade, there has been an explosion of informa-
tion regarding cell stress and cell death. These death pathways
may synergize and/or compete, each vying to deliver the fatal
blow. Importantly, the mechanisms of cell stress and cell death
are now recognized as critical determinants of the subsequent
immune response – impacting trafﬁcking of the APC, altering
the antigenic repertoire that is transferred upon phagocytosis and
inﬂuencing the cDC activation state (Albert, 2004). While most
studies have focused on apoptotic cell death vs. necrotic cell death,
there is increasing awareness that macroautophagy, within the
antigen donor cell, inﬂuences the outcome of cross-presentation.
Herein we focus on the ability of DCs to capture and cross-present
cell-associated antigen, reviewing in detail the recent evidence for
macroautophagy in the donor cell as an important mechanism for
facilitating antigen delivery to cDCs.
MACROAUTOPHAGY AND ANTIGEN PRESENTATION
Macroautophagy (referred to herein as autophagy) has been
deﬁned as an “auto-digestive” process that promotes the delivery
of intracytosolic components to lysosomal or vacuolar compart-
ments for terminal degradation and recycling (Deretic and Levine,
2009; Figure 1). Autophagy has distinct roles in different cellular
contexts and occurs at a basal level in all nucleated cells. Constitu-
tive autophagy is important for the turnover of unfolded proteins
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FIGURE 1 | Machinery of autophagy. Beclin-1/PI3K-III complex
activation, which is regulated by different mechanisms, results in the
formation of phosphatidylinositol 3-phosphate [PI(3)P1] and the induction
of an autophagic vesicle, which is characterized by a double-membrane,
and termed an autophagosome (Crotzer and Blum, 2010; Mehrpour
et al., 2010; Kang et al., 2011). Two ubiquitin-like systems have been
shown essential for autophagosome formation. In the ﬁrst,
autophagy-related gene-12 (Atg12) is conjugated to Atg5, together
forming a complex with Atg16L1, which decorate the outer membrane of
the isolation membrane. Microtubule-associated protein 1 light chain-3
(LC3, also known as Atg8) constitutes the second ubiquitin-like system
and conjugates phosphatidylethanolamine (PE) at the outer and inner
autophagosomal membrane. Unlike the Atg12/Atg5/Atg16L1 complex
that is recycled by the protease Atg4, the LC3-PE (referred to as LC3-II)
remains associated with the inner membrane of autophagosome
(Mehrpour et al., 2010). The incorporation of phospholipid into the
autophagosome membrane is essential for its elongation, and regulates
the membrane transport system. Autophagosome maturation is
characterized by the formation of an autolysosome, the product of fusion
with the lysosome.
or damaged organelles and maintains cellular homeostasis (Kroe-
mer et al., 2010). For example, autophagy is important for reducing
oxidative stress by selectively targeting damaged mitochondria
(Wang and Klionsky, 2011; Mai et al., 2012). Similarly, endoplas-
mic reticulum (ER), peroxisomes, ribosomes, protein aggregates,
and even intracellular pathogens may be eliminated via autophagy
(Yu et al., 2008; Joubert et al., 2009; Komatsu and Ichimura, 2010;
Mizushima and Komatsu, 2011). Autophagy is also considered
as part of the host response to cellular stress, including nutrient
deprivation or adenosine triphosphate (ATP) depletion. Under
such conditions, autophagy protects cells by supplying recycled
nutrients to support essential cellular process until restoration
of homeostasis. Autophagy induced by cellular stress is generally
considered to be a non-selective, bulk degradative process.
More recently, autophagy has been recognized as an impor-
tant modulator of host immunity, with a particular role for the
processing of antigen for presentation by MHC and the initiation
of adaptive immune responses (Dengjel et al., 2005; Deretic and
Levine, 2009; Crotzer and Blum, 2010). Speciﬁcally, autophagy
has been described to participate in the translocation of endoge-
nous protein into the MHC class II loading compartment, which
facilitates MHC class II presentation and CD4+ T cells activation
(Dengjel et al., 2005). As one key example, it has been demon-
strated that the constitutive degradation of cellular components
through autophagy provides a critical source of self antigen in the
thymus for education of CD4+ T cell precursors (Nedjic et al.,
2008). In addition to CD4+ T cell activation, there is now evi-
dence to suggest a role for autophagy – or at least autophagic
genes – in the generation of MHC I/peptide complexes, within
the APC. Based on early studies using silencing of Atg12 or Atg5,
or pharmacological inhibitors, it was argued that autophagy does
not have a major impact on MHC class I presentation of multi-
ple endogenous or exogenous antigens (Nimmerjahn et al., 2003;
Paludan et al., 2005; Lee et al., 2010). Moreover, conjugation of
a viral epitope to LC3 did not alter MHC class I presentation of
this epitope (Schmid et al., 2007). Recent data however, has chal-
lenged these conclusions, at least in the context of selected model
systems. Interestingly, inhibition of autophagy in IFN-γ-treated
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B16 mouse melanoma cells diminished MHC class I protein sur-
face expression and tumor cell cytolysis by CD8+ T lymphocytes
(Li et al., 2010). MHC class I presentation by these tumors was
proteasome dependent, suggesting a possible connection between
autophagy and the conventional pathway for MHC class I presen-
tation. In another study, the group of Desjardins has highlighted
an unconventional autophagy pathway that modulates MHC class
I presentation in macrophages infected by Herpes simplex virus
(HSV; English et al., 2009). Early after infection (6–8 h), viral cap-
sid antigen presentation in infected macrophages occurs via the
conventional MHC class I pathway, but during the late stages of
infection (8–12 h), viral capsid presentation is dependent on acidic
organelles as well as Atg5 expression. This study also reported that
HSV-infected cells contain speciﬁc andunconventional LC3+ vesi-
cles that are closely associated with the nuclear envelope. This led
the authors to suggest that virus infection induced a novel form
of autophagy, which may contribute to the escape of antigen into
the cytosol.
CONNECTING AUTOPHAGY AND CROSS-PRIMING
While basal or induced autophagy in APCs does not seem to
be strongly implicated in their ability to cross-present exogenous
antigen, some early evidence suggested a role for autophagy within
the antigen donor cell. In 2002, a study from Vile and colleagues
suggested for the ﬁrst time that autophagic vacuoles within the
donor cell could be correlated with efﬁcient cross-priming of
associated-antigens (Bateman et al., 2002). Viral fusogenic mem-
brane glycoprotein (FMGs) had been known to kill solid tumor
cells after the formation of large multinucleated syncytia. The
authors observed that FMG-mediated killing of syncytia was not
dependent on a classical apoptosis pathway. Instead, death of syn-
cytia was associated with nuclear fusion and premature chromo-
some condensation as well as severeATP depletion (Bateman et al.,
2002). Interestingly, cytoplasmic vacuoles were demonstrated to
be acidic, suggesting that the death of syncytia was correlated with
autophagic activity. In the same study, the authors demonstrated
that FMG-mediated death was accompanied by release of vesicles
reminiscent of exosomes,which they called syncitiosomes. Impor-
tantly, dying syncytia produced signiﬁcantly more syncitiosomes
than normal cells or cells killed by pro-apoptotic or pro-necrotic
signals, including irradiation, freeze thaw, or osmotic shock (Bate-
man et al., 2002). These syncitiosomes served as an efﬁcient source
of antigen for cDCs, out-performing classical exosomes, or dead
cell corpses. Lacking from this study, however, was the mechanis-
tic association of Atg proteins with death of syncytia and effective
cross-priming.
An additional clue linked autophagy to the removal of apoptotic
corpses in mouse embryoid bodies (EBs) and during chick retinal
development (Qu et al., 2007; Mellen et al., 2008). In both stud-
ies, autophagy is required for dying cells to have sufﬁcient energy
to generate the engulfment signals necessary for the clearance of
corpses by phagocytes. Indeed, EBs derived from cells lacking
autophagy genes (e.g., atg5 or beclin-1), failed to express “eat-
me” signal such as phosphatidylserine (PS) exposure, and secreted
lower levels of “come-get-me” signals, such as lysophosphatidyl-
choline (LPC; Qu et al., 2007). These defects were associated with
low levels of cellular ATP and could be reversed by treatment
with the metabolic substrate, methyl pyruvate. Similar results
were observed after treatment of retinas with 3-methyladenine
(3-MA), a pharmacological inhibitor of autophagy (Mellen et al.,
2008). Extrapolation of these studies might suggest another mech-
anism by which autophagy regulates cross-presentation. Indeed,
the role of autophagy in metabolism may be generally relevant for
phagocyte function, and aspects of innate and adaptive immune
responses.
AUTOPHAGY WITHIN TUMOR CELLS FAVORS
CROSS-PRIMING OF TUMOR-ASSOCIATED
ANTIGEN-SPECIFIC CD8+ T CELLS
Seminal studies from Hu and colleagues illustrated a direct role
for autophagy in the cross-priming of associated-antigen (Li et al.,
2009). In their initial studies, HEK 293T cells expressing oval-
bumin (V-TfR-GFP-OVA) or melanoma cells that endogenously
express the gp100 tumor antigen were used as antigen donor
cells (ADC). The authors showed that autophagy in ADC regu-
lates the efﬁciency of cross-presentation both in vitro and in vivo
(Li et al., 2009). Inhibition of autophagy with 3-MA or siRNA
knockdown of the essential autophagic genes beclin-1 and Atg12,
demonstrated that early steps of autophagy – including initiation
and elongation of the double-membrane structure, sequestration
of cytosolic antigens, and formation of autophagosomes – were
required for efﬁcient antigen cross-presentation. Providing addi-
tional support, drug, or stress-induced autophagy (i.e., treatment
with rapamycin or starvation) resulted in enhanced cross-priming
of OVA or gp100-speciﬁc CD8+ T cells. In these studies, it is
important to note that late steps of autophagy, including late lyso-
somal fusion and degradation, seemed to have little impact on
antigen cross-presentation (Li et al., 2009). Perhaps most inter-
estingly, autophagosomes were isolated, puriﬁed, and exposed
to DCs, demonstrating efﬁcient delivery of antigen and cross-
presentation (Li et al., 2009). Future studies will be required to
conﬁrm that contaminating microsomes or secreted exosomes did
not contribute to antigen transfer in these experiments.
More recently, the same group observed that isolated
autophagosomes from dying tumor cells expressed not only long-
lived protein – well know to be sequestered in autophagosomes –
but also short-livedproteins (SLiPs), includingdefective ribosomal
initiation products (DRiPs; Yewdell et al., 1996; Li et al., 2011).
Immunization with these autophagosomes – named “Dribbles”
by the authors to refer to DRiPs-containing blebs – were effec-
tive in initiating tumor immunity and inducing the regression
of 3LL Lewis lung tumors as well as delaying growth of B16F10
melanoma. Strikingly, DRibbles were more potent than GM-CSF
gene modiﬁed tumor cells. Importantly, DRibble-derived antigen
processing by cDCs was mediated by classical components of the
MHC I processing machinery, including TAP1 and proteasome,
and it did not involve the lysosomal pathway of the cDC (Li et al.,
2011). These observations suggested that DRibble-derived antigen
must be released into the cytosol after phagocytosis to be processed
by the classical MHC class I pathway. Although mechanisms by
which DRibbles could favor antigen cross-presentation remain to
be conﬁrmed, these studies were the ﬁrst to identify capture of
autophagosome-associated antigen as a mechanism for achieving
tumor immunity.
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VIRUS-MEDIATED ABORTIVE AUTOPHAGY ENHANCES
ANTIGEN CROSS-PRIMING
Studies from our own laboratory have also identiﬁed an important
role for autophagy within the ADC, serving to enhance antigen
cross-priming of CD8+ T cells (Uhl et al., 2009). The experimen-
tal system employed permitted direct comparison between two
forms of programmed cell death (PCD): (i) the classical caspase-
dependent apoptosis, which it occur in wild-type (WT) mouse
embryonic ﬁbroblast (MEFs); and (ii) caspase-independent cell
death, which occurs with increased features of autophagy, and
achieved experimentally through the use of Bax−/−/Bak−/− MEFs
(Shimizu et al., 2004). Both cell types were infected with inﬂuenza
A virus as a source of antigen, followed by UV irradiation –
serving to both inhibit viral replication and induce genotoxic
stress – and injected in vivo as a source of antigen for studying the
efﬁciency of cross-priming (Uhl et al., 2009). Interestingly, mice
immunized with cells undergoing enhanced autophagy showed
a signiﬁcantly higher CD8+ T cell response speciﬁc for both
HA518–526 (in Balb/c hosts) and NP366–374 (in C57BL/6 hosts).
Strikingly, silencing of the essential autophagic gene Atg5 in both
WT and Bax−/−/Bak−/− MEFs inhibited antigen cross-priming.
Careful evaluation of inﬂuenza infected WT MEFs indicated that
viral infection induced accumulation of autophagosomes, now
known to be a result of inﬂuenza M2-inhibition of autophago-
some/lysosome fusion (Gannage et al., 2009). Notably, inﬂuenza
infection is capable of inducing both autophagy and apoptosis;
different from other triggers of cell stress and cell death, these
two processes can be found simultaneously within the same cell
(de la Calle et al., 2011). We argue that the ﬁnding of double
positive cells – co-labeled with anti-caspase 3 antibodies and har-
boring LC3 punctae – is a result of abortive autophagy. This is
supported by studies using chloroquine (de la Calle et al., 2011),
which interestingly, has also been shown to enhance antigen cross-
priming (Accapezzato et al., 2005), and is currently being tested
in combination with rapamycin as a means of inducing in situ
tumor immunity (Amaravadi et al., 2011). Additional work is
required in order to establish abortive autophagosomes as the crit-
ical source of antigen for facilitating efﬁcient transfer from donor
cells to cDCs.
AUTOPHAGY MAY FAVOR RELEASE OF “IMMUNOGENIC”
PROTEINS
The ﬁrst established link between autophagy genes and pro-
inﬂammatory responses was established in plasmacytoid DCs
(pDCs), with the demonstration that Atg5 is involved in
autophagy-mediated delivery of TLR7 agonists from the cytosol
of infected cells into the lumen of the endosome, thus accounting
for induction of type I interferon (IFN; Lee et al., 2007). Some-
what paradoxically, several studies have shown that the absent or
hypomorphic expression of autophagic genes in certain cell types
can result in enhanced production of type I interferon or other
cytokines; including pro-inﬂammatory molecules such as IL1β
and IL-18,aswell as adipocytokines, such as leptin and adiponectin
(Jounai et al., 2007; Cadwell et al., 2008; Saitoh et al., 2008; Tal
et al., 2009). Thus, autophagy machinery could have a dual func-
tion in regulating cytokine production,actingnot only to stimulate
antiviral type I IFN responses in pDCs, but may also limit excess
innate immune activation in other cell type, including ﬁbroblasts.
Alternatively, autophagy genes may differentially regulate distinct
PRRs: enhancing TLR engagement through the delivery of lig-
ands into the endosome;while inhibiting cytosolic sensors through
direct or indirect mechanisms.
Deﬁning how autophagy alters the inﬂammatory milieu is an
important issue, as type I IFNs has been shown to regulate antigen
cross-priming (Jounai et al., 2007;Uhl et al., 2009;Wei et al., 2010).
Using the same model as previously described, our group has
demonstrated that mice immunized with Bax−/−/Bak−/− dying
cells – undergoing high level of autophagy – induced in cDCs a
signiﬁcantly higher type I IFN production in cDCs as compared
to mice immunized with WT MEFs (Uhl et al., 2009). Supporting
a role for type I IFN, it was shown that immunization of mice deﬁ-
cient for the IFNα/β receptor (IFNAR) resulted in a dramatically
reduced cross-priming response (Uhl et al., 2009). The mecha-
nism by which autophagy within dying cells favors the production
of type I IFN by APCs remains to be deﬁned; one possibility is
that viral nucleic acids present in the autophagic corpse serves to
engage sensors within the phagocytic cDC (Schulz et al., 2005).
In addition to pro-inﬂammatory cytokines, other “immuno-
genic proteins” may be released during autophagic processes,
which in turn favor cross-priming. For example, the high-mobility
group box 1 protein (HMGB1) provides an interesting connec-
tion between autophagy and cross-priming. HMGB1 is a highly
conserved chromatin-binding protein that facilitates DNA bend-
ing and promotes transcription (Maruyama, 2011). In addition to
its intra-nuclear role, HMGB1 also functions as an extracellular
signaling molecule and can interact with at least three different
surface receptors that are expressed on APC, namely the receptor
for advanced glycosylation (RAGE), TLR2, and TLR4 (Nogueira-
Machado et al., 2011). The binding of HMGB1 to TLR4 may not
be a direct interaction as recent data indicates that HMGB1 chap-
erones LPS (Yang et al., 2012), as well as other PRR ligands (Yanai
et al., 2009). Indeed, the role of HMGB1 as a co-factor for PAMPs
may be central to its role in stimulating the processing and presen-
tation of derived antigens. Importantly, secretion of HMGB1 by
dying tumor cells has been shown to inhibit fusion of the APC’s
phagosome with lysosomes, thereby preventing rapid degradation
of tumor antigens and enabling processing and presentation onto
MHC I (Apetoh et al., 2007). Furthermore, Scafﬁdi et al. (2002)
showed that HMGB1 participates in the recruitment of phago-
cytes. Indeed, HMGB1−/− cells have a greatly reduced ability to
promote inﬂammation,which indicates that the release of HMGB1
can signal the demise of a cell to its neighbors. While initial stud-
ies indicated that HMGB1 is released (passively) from necrotic
cells and that during apoptosis HMGB1 becomes hypoacetylated
and remains bound to the chromatin of the dying cell (Sims
et al., 2010), the biology now seems a bit more complex. Recent
work from Ferguson and colleagues indicate that the redox state,
in addition to the acetylation state, may impact the bioactivity
of HMGB1 (Kazama et al., 2008). ROS mediated oxidation of
HMGB1 inhibited its pro-inﬂammatory potential. The authors
went on to demonstrate that oxidation was caspase-dependant,
acting via the cleavage of mitochondrial components of the elec-
tron transport system (Kazama et al., 2008). Based on the ability of
autophagic processes to limit accumulation of ROS, it is interesting
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to consider that this may contribute to the pro-inﬂammatory
effects of autophagy within dying ADC. This hypothesis is sup-
ported by evidence that HMGB1 released from autophagic tumor
cells is immune stimulatory (Thorburn et al., 2009). Inhibition of
autophagy resulted in HMGB1 retention, and in the induction of
caspase-mediated cell death. The mechanism by which autophagy
regulates secretion of HMGB1 remain unknown, but seems to
be occurring in a manner similar to other leaderless cytokines.
Indeed, exogenous HMGB1 can modulate the future of tumor
cells and reduced HMGB1 induced pro-survival autophagy via
the activation of RAGE receptor and beclin-1 whereas oxidized
HMGB1 favored activation of caspase-9 and -3 that lead to apop-
totic cell death (Tang et al., 2010). Thus, autophagy could favor
the release of reduced HMGB1 by limiting cytoplasmic ROS level;
in turn reduced HMGB1 may increase autophagy in neighboring
cells as well as activate the recruitment of immune cells, stimulate
cytokines secretion, and facilitate antigen cross-priming.
Other immunogenic signals may also be regulated by
autophagy, including exposure of PS and secretion of LPC (Qu
et al.,2007;Mellen et al., 2008).Recently, the groupsof Zitvogel and
Kroemer established a link between autophagy and ATP release
during chemotherapy treatment (Michaud et al., 2011). This study
showed that autophagy is dispensable for chemotherapy-induced
cell death but required for its immunogenicity both in vitro and
in vivo. In response to chemotherapy, autophagy-competent, but
not Atg5 or Atg7 -shRNA transfected tumors, were capable of
recruiting cDCs andT cells into the tumormicro-environment, via
ATP mediated chemoattraction. Although this work did not for-
mally show T cell cross-priming, it helped establish a new concept
related to autophagy regulationof immunity. Further investigation
FIGURE 2 | Autophagy within antigen donor cells and cross-priming.
(A)The process of autophagy within stressed or dying cells has been
demonstrated to enhance recruitment of antigen presenting cells (APCs)
and phagocytosis. For example, in response to chemotherapy, autophagy
within cancer cells favors the release of ATP and enhances the recruitment
of cDC andT cells into the tumor micro-environment (Michaud et al., 2011).
In addition, the release of ATP triggers the exposure of “eat-me” signal
(e.g., PS) and the release of “come-get-me” signal (e.g., LPC), an essential
feature of efﬁcient capture of dying cells by APC (Qu et al., 2007; Mellen
et al., 2008). Autophagy can also be involved in the release of other
“immunogenic proteins” known to support the cross-priming (e.g.,
HMGB1). The mechanism by which autophagy regulates the release of
HMGB1 remain to be determined. (B) Free autophagosome containing
antigen – passively released following cell death or actively secreted – may
be recognized directly by APC, inducing a signal transduction pathway that
leads to increased cross-presentation. One example includes
DRibbles-derived antigen cross-priming that is partially dependent of
CLEC9A (Li et al., 2011). These data suggest that autophagosome express
the ligand of CLEC9A, which is recognized by APC to enhance
cross-priming. (C) Blocking autophagic ﬂux in antigen donor cells – using
pharmacological inhibitor or during inﬂuenza A infection – favors antigen
cross-priming (Uhl et al., 2009). In this context, it is possible that inhibition
of lysosomal fusion serves to protect epitope within the autophagosome of
dying cells and facilitates delivery of intact or partially processed antigen to
APC. In addition, the capture of intact autophagosome could enhance
cytokine production (e.g., type I interferon) and cDC activation.
www.frontiersin.org March 2012 | Volume 3 | Article 61 | 5
Joubert and Albert Autophagy and cross-priming
regarding other secreted and/or exposed proteins would help fur-
ther clarify the mechanisms by which autophagy within ADC
favors antigen cross-priming.
AUTOPHAGIC FLUX OR AUTOPHAGOSOMES?
One critical unknown concerns the cell biology of autophagy
within ADC as it relates to protection and delivery of anti-
gen to APCs. Some evidence suggests that autophagosomes, but
not necessarily autophagic ﬂux, are required for efﬁcient cross-
priming. This is supported by the importance of early steps of
autophagy – including initiation and elongation of the double-
membrane structure, sequestration of cytosolic antigens, and
formation of autophagosomes – for achieving efﬁcient antigen
cross-presentation of tumor cells (Li et al., 2009, 2011). Addition-
ally, our own studies indicate that blocking autophagic ﬂux within
dying cells enhanced the cross-priming of viral antigens (Giodini
and Albert, unpublished data). Accumulation of autophagosomes
may also account for the seminal observations of Barnaba and
colleagues, who shown that chloroquine enhance cross-priming
(Accapezzato et al., 2005). In this context, it is possible that inhi-
bition of lysosomal fusion serves to protect epitope within the
autophagosome of dying cells and facilitates delivery of intact or
partially processed antigen to APC.
One ﬁnal consideration is the capture of free autophagic vesi-
cles – passively released following cell death or actively secreted
via a mechanism referred to as exophagy (Abrahamsen and Sten-
mark, 2010) – could be recognized by APCs as a source of antigen
or immunogenic signals to enhance cross-priming. It has indeed
been demonstrated in vitro that tumor cell-derived autophago-
somes can be isolated from culture media; and may engage the
C-type lectin receptor, CLEC9A (Li et al., 2011). These data may
extend the previous role for CLEC9A as a receptor for necrotic cells
and amediator of efﬁcient SYK-dependant cross-priming (Sancho
et al., 2009).
CONCLUSION
In addition to cell death pathways, increasing evidence indicates
an important role for cell stress, within ADC, as a regulator
of adaptive immune responses. Autophagic processes have been
shown to enhance the delivery of tumor and viral antigen to
cDCs. Moreover, autophagy triggers release of immunostimula-
tory proteins (e.g., HMGB1) and bioactive molecules (e.g., LPC,
ATP), which together favor recruitment and activation of the APC
(Figure 2).Oncewithin thephagosome,autophagic cellsmay serve
as stimulators of PRRs, further enhancing the phagocyte’s cross-
priming potential. Another interesting line of investigation will
be the autophagosome itself, which may serve to protect antigen
from degradation and facilitate delivery APCs. A detailed evalu-
ation of how autophagy favors cross-priming may help launch
new immunotherapy strategies for treating cancer or chronic
disease. Moreover, it may provide a mechanistic understand-
ing of currently used chemotherapies (e.g., cyclophosphamide or
methotrexate) or experimental compounds (e.g., rapamycin given
in combination with hydroxychloroquine).
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